Tech & Gadgets

Biossil hits unicorn status with new OpenAI-led financing

30 sec read9 views0 listens

Toronto-based biotech firm Biossil has achieved unicorn status, securing $153 million USD in a funding round spearheaded by OpenAI’s Startup Fund. This development highlights the growing intersection of artificial intelligence and drug development, as Biossil utilizes AI to revive previously failed drug projects, offering a potentially faster and more efficient path to new treatments. Investors should watch for further details on Biossil's pipeline expansion and the specific AI-driven insights that will inform their clinical trials.

Read the full article at BetaKit

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Ali NematiBlogUI.author_articles

BlogUI.view_profile

You Might Like

Cybersecurity5 hours ago28 sec read

Building an evidence-grounded agentic security operations harness on Cloudflare

Cloudflare has introduced a new security operations harness leveraging multiple AI agents to address the challenges of alert overload for security analysts. This system moves beyond single-agent approaches, which proved prone to inaccuracies, by empl...

Ali Nemati

AI & Machine Learning5 hours ago35 sec read

The Optimal Stopping Illusion

Recent research has revealed that language agents, despite accurately assessing the quality of retrieved information, frequently ignore this judgment when deciding whether to continue a search process. This disconnect stems from the fact that current...

Ali Nemati

AI & Machine Learning5 hours ago32 sec read

The Hidden Performance Ceiling of React Native Skia in Production

The use of React Native Skia, often touted as a performance enhancement, can introduce unexpected issues in production environments, particularly when rendering high-frequency data like real-time physiological waveforms. Developers often overlook tha...

Ali Nemati